Three’s A Crowd: Cimzia Joins Humira, Remicade For Crohn’s Disease

UCB is pushing pricing and other incentives for Cimzia (certolizumab) - rather than clinical benefit - to break into a crowded Crohn's disease market that already includes two well-established tumor necrosis factor inhibitors